Small molecule inhibitors of replication protein A that also act synergistically with cisplatin
View Patent ↗Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 μM. The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC 50 values below 3 μM. Sequential treatment with MCI13E and cisplatin resulted in synergism, suggesting that decreasing RPA's DNA binding activity via a SMI may disrupt RPA's role in cell cycle regulation. Thus, RPA SMIs hold the potential to be used as single agent chemotherapeutics or in combination with current chemotherapeutic regimens to increase their efficacy.
1. A method of inhibiting Replication Protein A, comprising the steps of:
contacting a halo-ester isoborneol substituted with at least one halogen selected from the group consisting of fluorine, chlorine, bromine and iodine with a molecule of Replication Protein A, wherein said halo-ester isoborneol at least partially inhibits the activity of Replication Protein A.
2. The method according to claim 1 , wherein said halo-ester isoborneol is selected from the group consisting of: TDLR-003, MCI13E, and MCI13F.
3. The method according to claim 1 , wherein the contacting step occurs in an application area selected from the group consisting of: in vitro and in vivo.
4. A method of inhibiting eukaryotic cell viability, comprising the step of: contacting a halo-ester isoborneol substituted with at least one halogen selected from the group consisting of fluorine, chlorine, bromine and iodine with a eukaryotic cell, wherein said halo-ester isoborneol inhibits Replication Protein A.
5. The method according to claim 4 , wherein the eukaryotic cell is a cancer cell.
6. The method according to claim 4 , further including the step of:
dosing the eukaryotic cell with at least one compound that damages DNA in vivo.
7. The method according to claim 6 , wherein the compound that damages DNA in vivo promotes the formation of intrastrand linkages between adjacent nucleotides.
8. The method according to claim 7 , wherein the compound that damages DNA is cis-diamminedichloroplatinum[III].
9. The method according to claim 6 , wherein the step of dosing the cells with the compound that damages DNA occurs before the step of contacting the cells with said halo-ester isoborneol.
10. The method according to claim 4 , wherein said halo-ester isoborneol is selected from the group consisting of: TDLR003, MCI13E, and MCI13F.